Form D · Biotechnology
Novo Biosciences, Inc.
Lamoine, ME · CIK 0001648277
Offering snapshot reported Jun 9, 2020 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $4M Reported outside-investor minimum
- First sale
- May 28, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 9, 2020 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
| Jul 16, 2015 | Initial | $75,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-368583
Source: Form D, filed Jun 9, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Denise Barbut | Director |
| Daniel Coit | Director |
| Kevin Strange | Director, Executive |
| Viravuth Yin | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
22 Partridge Cove Road
Lamoine, ME, 04605
Lamoine, ME, 04605